Lymphatics in Liver Diseases

Lymphatics in Liver Diseases

Administration of VEGF-C or D may ameliorate benign liver diseases by increasing lymphangiogenesis and lymphatic drainage. Blocking lymphangiogenesis could also be an appropriate option for diseases such as cholangiocarcinoma where tumor-induced lymphangiogenesis may promote metastasis of malignant tumors. Identification of alternative lymphangiogenic pathways other than the VEGF-C/D/VEGFR3 axis, including additional pro- and anti-lymphangiogenic factors will likely increase novel therapeutic options for cholangiocarcinoma in particular and liver diseases in general. Exciting times are waiting ahead. A completely new era of therapeutics in liver diseases and portal hypertension is likely to unravel in the near future.

Dr. Akash Shukla

Dr. Akash Shukla is an Director and Consultant in Department, Hepatology at Sir H. N. Reliance Foundation Hospital and Research Centre. He has completed his MBBS, MD-(Medicine) and DM-(Gastroenterology). He has published over 86 original research papers.


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks